Douglas J. Rhee, MD

106Drug Trade Preparation Usual Dose Notesverteporfin Visudyne Soln, 2 mg/ml (supplied as See Appendix 7 For photodynamic therapy for subfoveal15 mg of lyophilized choroidal neovascularizationpowder to be diluted in7.5 ml of sterile water)pegaptanib sodium Macugen 0.3 mg intravitreal Q6 Note: Approved by the FDA for all subtypesweeks (predominantly classic, minimally classic,occult) of CNV secondary to age-relatedmacular degeneration 1ranibizumab Lucentis 0.3 mg or 0.5 mg Approved by the FDA for CNV secondary tointravitreal Qmonth AMDbevacizumab Avastin 1.25 mg intravitreal Intravitreal injection of bevacizumab is an offlabeluse of the drug. there are no randomizedclinical trials of its use for maculardegeneration 2triamcinolone acetate Kenalog 4.0 mg intravitreal Intravitreal injection of triamcinolone acetate has20 mg intravitral been used in the treatment of macular edema ofvarious etiologies and for CNVM secondaryto AMD (particularly in combination withphotodynamic therapy)1 From N Engl J Med 2004; 351: 2805–2816.2 From Ophthalmology 2006;113:363–372.